AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01305928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fax
Description: Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge
Study NCT01758874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebotomy
Description: repeated phlebotomy for 4 weeks
Study NCT03236922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pubococcygeus sling
Description: The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
Study NCT03236922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus fascia sling
Description: Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
Study NCT02578511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
Study NCT02085343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXP
Description: Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
Study NCT02085343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXP
Description: Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
Study NCT02085343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXP + SBF
Description: Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
Study NCT02085343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXP + SBF
Description: Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
Study NCT02085343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXP + SBF + AA
Description: Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
Study NCT00284908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Tenatoprazole-Na (STU-Na)
Description: 30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
Study NCT01811940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-ER
Description: MAS-ER 60mg/day
Study NCT01811940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 100 mg bid.
Study NCT01811940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR Oxycodone
Description: PR Oxycodone
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone Placebo
Description: Placebo of PR Oxycodone
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Placebo
Description: Placebo of PR Oxycodone
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa placebo
Study NCT02601586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa placebo
Study NCT01794117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
Study NCT03132623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: andrographolide sulfonate
Description: Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
Study NCT03132623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: andrographolide sulfonate simulation
Description: Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
Study NCT03881033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peep 5cmH2O
Description: Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
Study NCT03881033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peak inspiratory pressure
Description: Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
Study NCT00042796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00042796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00042796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00796536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Description: Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
Study NCT00796536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
Study NCT03017144 — intervention group
Intervention type: OTHER
Intervention: Pit crew model education
Description: A pit crew model for resuscitation is educated to all resuscitation team members.
Study NCT02283437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving Based Bibliotherapy Program
Description: The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
Study NCT02283437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Management and Education Program
Description: Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
Study NCT04380896 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
Study NCT04380896 — intervention group
Intervention type: OTHER
Intervention: Standardised questionnaires
Description: It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 1.1
Description: In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 2.1
Description: In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 1.2
Description: In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 1.3
Description: In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 1.4
Description: In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 2.2
Description: In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 2.3
Description: In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AT case 2.4
Description: In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR Case 1
Description: In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
Study NCT03343860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR Case 2
Description: In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)
Study NCT00180713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg od for 1 month, then 80mg od for 11 months
Study NCT00180713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study NCT03784352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A calming virtual reality game will be played
Study NCT00405704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
Study NCT00405704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cherry flavored liquid suspension matched to active comparator.
Study NCT03406702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker
Study NCT04520555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
Study NCT04520555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
Study NCT03467308 — intervention group
Intervention type: GENETIC
Intervention: Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)
Description: The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods.
Study NCT01744925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib of routine dose
Description: Icotinib: 125mg, oral administration, three times per day.
Study NCT01744925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib of high dose
Description: Icotinib: 375mg, oral administration, three times per day.
Study NCT03027687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is an electrical brain stimulation method
Study NCT03027687 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS is an electrical brain stimulation method
Study NCT04660019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp and auricular acupuncture
Description: Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.
Study NCT04660019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Seed acupressure
Description: Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
Study NCT02768558 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: 2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
Study NCT02768558 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy (RT)
Description: 2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
Study NCT02768558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
Study NCT02768558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
Study NCT02768558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
Study NCT02768558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
Study NCT02768558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Study NCT02768558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Study NCT03396432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy for ET placement
Description: Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
Study NCT03396432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy for ET Placement
Description: Tracheal Intubation performed with the Miller Blade
Study NCT00406458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: 60 mg dose
Study NCT00406458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT03018301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
Study NCT03018301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
Study NCT03222544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
Study NCT03222544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Photon therapy instrument
Description: Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand